Skip to search formSkip to main contentSkip to account menu

efatutazone

Known as: 2,4-Thiazolidinedione, 5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-, Inolitazone, Rac-5-((4-((6-(4-Amino-3,5-Dimethylphenoxy)-1-Methyl-1H-Benzimidazol-2-yl)Methoxy)Phenyl)Methyl)-1,3-Thiazolidine-2,4-Dione 
An orally bioavailable thiazolidinedione and an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Antineoplastic AgentsThiazolidinediones

Narrower (2)

CS 7017RS 5444
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Biotinylation enhances the anticancer effects of 15d‑PGJ2 against breast cancer cells.
15-Deoxy-∆12,14-prostaglandin J2 (15d‑PGJ2) is a natural agonist of peroxisome proliferator-activated receptor γ (PPARγ) that… 
2018
2018
Studies of Breast Cancer Chemoprevention in Human High-Risk Primary Cells and Genetically Engineered Mouse Models
BRCA1 mutations have been associated with a 50-80% increased risk of developing breast cancer by the age of 70. Current… 
2017
2017
Abstract 2234: Efatutazone reduces mammosphere formation inBrca1WT/fl11/Cre/p53+/-andBrca1fl11/fl11/Cre/p53+/-mice
2014
2014
Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Efatutazone is a potent, highly selective… 
2014
2014
Therapeutics , Targets , and Chemical Biology Small Molecule Agonists of PPAR-g Exert Therapeutic Effects in Esophageal Cancer
The transcription factor PPAR-g plays various roles in lipid metabolism, inflammation, cellular differentiation, and apoptosis… 
2013
2013
New combination treatment for anaplastic thyroid cancer
2013
2013
Abstract 5511: The proliferation-inhibiting effects of Efatutazone, a novel third-generation peroxisome proliferator-activated receptor gamma agonist, on esophageal squamous cell carcinomain…
Background: Peroxisome proliferator-activated receptor gamma (PPARγ) inhibits the proliferation of several cancers. Efatutazone… 
2012
2012
Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Efatutazone, a highly-selective… 
2011
2011
9059 POSTER Phase 1b Study of Oral PPAR-gamma Agonist Efatutazone (CS-7017) in Combination With Carboplatin and Paclitaxel in Chemotherapy-Naive Korean Patients With Metastatic or Unresectable…
2011
2011
1238 POSTER Phase 1 Clinical Trial of Oral PPAR – Agonist Efatutazone (CS-7017) in Japanese Patients With Metastatic Solid Tumours
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)